July 20, 2026

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

Conexiant

July 14, 2026

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

Conexiant

July 14, 2026

Autism Spectrum Disorder Linked to Distinct Urine Metabolite Pattern

Researchers proposed a new autism spectrum disorder phenotype characterized by elevated urinary microbially derived metabolites.

Conexiant

July 08, 2026

Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.

Conexiant

July 02, 2026

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

Conexiant

July 02, 2026

Does Structured Reporting Improve Lung Cancer Reports?

A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.

Conexiant

July 01, 2026

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Conexiant

June 29, 2026

Alternative Isoforms May Refine Variant Interpretation

Long-read transcript sequencing uncovered protein-altering variants missed by reference transcript analyses and identified functional effects for a lung-specific DPP9 isoform.

Conexiant

June 26, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Conexiant

June 18, 2026

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Conexiant